Medical Doctor Program year 2019 Source: CMS Open Payments, 2026 publication

Andriana Nikolova

Cardiovascular Disease Beverly Hills, CA Medical Doctor

NPI 1841551694 CMS profile 842631

8670 Wilshire Blvd Ste 200, Beverly Hills, CA 90211

Open in the dashboard

General payments

$207

3 records reported · program year 2019

Research payments

$0

Paid to them · None reported · program year 2019

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$979,768 paid to institutions, not to them · program years 2022–2025

Through program year 2019, Andriana Nikolova of Beverly Hills, CA is reported in the CMS Open Payments database as having received $207 across 3 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $979,768 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 17th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2019 General $207 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andriana Nikolova
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Andriana Nikolova were reported at $0. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Andriana Nikolova Cardiovascular Disease median Middle half National median
2019 $207 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $0 $443 $136–$1,283 $160
2024 $0 $450 $136–$1,323 $164
2025 $0 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program year 2019
  1. Abbott Laboratories $183 2 payments
  2. Edwards Lifesciences Corporation $25 1 payment

Every payment, record by record

What the payments were for General payments · program year 2019
  1. Food and Beverage $207 3 payments
Products named General payments · program year 2019
  1. Quadra Allure MP RF CRT Pacemkr $100 1 payment
  2. CardioMEMS HF System $83 1 payment
  3. Edwards SAPIEN 3 Transcatheter Heart Valve $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,663

Median for Cardiology: 2,533

Drug cost

$1,333,261

Median for Cardiology: $485,213

Branded share of claims

26.1%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 47 $1,068,678
Eliquis Apixaban Brand 54 $64,143
Entresto Sacubitril/Valsartan Brand 46 $53,018
Repatha Sureclick Evolocumab Brand 57 $47,016
Farxiga Dapagliflozin Propanediol Brand 27 $30,538
Xarelto Rivaroxaban Brand 15 $23,179
Praluent Pen Alirocumab Brand 29 $17,229
Tacrolimus Generic 31 $5,294
Valganciclovir Hcl Generic 17 $4,349
Rosuvastatin Calcium Generic 176 $2,216

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$138,553

Medicare's payments for the services billed

Medicare patients

637

Average age 72

Services billed

1,604

283 women, 354 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 61%
Heart failure 50%
Diabetes 47%
Chronic kidney disease 47%
Arthritis 47%
Atrial fibrillation 34%
Cancer 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

3 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2019

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record